Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Nephrol Dial Transplant. 2023 Jan 23;38(1):119-128. doi: 10.1093/ndt/gfac197.
While American nephrology societies recommend using the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) estimated glomerular filtration rate (eGFR) equation without a Black race coefficient, it is unknown how this would impact disease distribution, prognosis and kidney failure risk prediction in predominantly White non-US populations.
We studied 1.6 million Stockholm adults with serum/plasma creatinine measurements between 2007 and 2019. We calculated changes in eGFR and reclassification across KDIGO GFR categories when changing from the 2009 to 2021 CKD-EPI equation; estimated associations between eGFR and the clinical outcomes kidney failure with replacement therapy (KFRT), (cardiovascular) mortality and major adverse cardiovascular events using Cox regression; and investigated prognostic accuracy (discrimination and calibration) of both equations within the Kidney Failure Risk Equation.
Compared with the 2009 equation, the 2021 equation yielded a higher eGFR by a median [interquartile range (IQR)] of 3.9 (2.9-4.8) mL/min/1.73 m2, which was larger at older age and for men. Consequently, 9.9% of the total population and 36.2% of the population with CKD G3a-G5 was reclassified to a higher eGFR category. Reclassified individuals exhibited a lower risk of KFRT, but higher risks of all-cause/cardiovascular death and major adverse cardiovascular events, compared with non-reclassified participants of similar eGFR. eGFR by both equations strongly predicted study outcomes, with equal discrimination and calibration for the Kidney Failure Risk Equation.
Implementing the 2021 CKD-EPI equation in predominantly White European populations would raise eGFR by a modest amount (larger at older age and in men) and shift a major proportion of CKD patients to a higher eGFR category. eGFR by both equations strongly predicted outcomes.
尽管美国肾脏病学会建议在没有黑人系数的情况下使用 2021 年慢性肾脏病流行病学合作(CKD-EPI)估算肾小球滤过率(eGFR)方程,但尚不清楚这将如何影响主要为白人的非美国人群中的疾病分布、预后和肾衰竭风险预测。
我们研究了 160 万在 2007 年至 2019 年期间进行血清/血浆肌酐测量的斯德哥尔摩成年人。我们计算了当从 2009 年 CKD-EPI 方程更改为 2021 年 CKD-EPI 方程时,eGFR 的变化以及在 KDIGO GFR 类别中的重新分类;使用 Cox 回归估计 eGFR 与肾衰竭伴替代治疗(KFRT)、(心血管)死亡率和主要不良心血管事件之间的关联;并在 Kidney Failure Risk Equation 中研究了两种方程的预后准确性(区分度和校准度)。
与 2009 年方程相比,2021 年方程产生的 eGFR 中位数[四分位距(IQR)]高 3.9(2.9-4.8)mL/min/1.73m2,在年龄较大和男性中更高。因此,总人群中有 9.9%和 CKD G3a-G5 人群中有 36.2%被重新分类到更高的 eGFR 类别。与具有相似 eGFR 的非重新分类参与者相比,重新分类的个体的 KFRT 风险较低,但全因/心血管死亡和主要不良心血管事件的风险较高。两种方程的 eGFR 均强烈预测研究结局,对于 Kidney Failure Risk Equation,具有相同的区分度和校准度。
在主要为白种人欧洲人群中实施 2021 年 CKD-EPI 方程将使 eGFR 适度增加(在年龄较大和男性中更大),并将大部分 CKD 患者转移到更高的 eGFR 类别。两种方程的 eGFR 均强烈预测结局。